An Open-Label 52-week Study to Assess the Long-Term Safety of NKTR-118 in Opioid-Induced Constipation (OIC) in Patients With Non-Cancer-Related Pain.

Trial Profile

An Open-Label 52-week Study to Assess the Long-Term Safety of NKTR-118 in Opioid-Induced Constipation (OIC) in Patients With Non-Cancer-Related Pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 May 2015

At a glance

  • Drugs Naloxegol (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Registrational
  • Acronyms KODIAC-08
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 May 2015 Results published in Digestive Disease Week, according to a Daiichi Sankyo media release.
    • 16 May 2015 Results published in a Daiichi Sankyo media release.
    • 16 Sep 2014 Naloxegol was approved in the US for the treatment of opioid-induced constipation, based on data from this and other trials in the phase III KODIAC programme.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top